10 / 10
Volume 08
Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Page 50
August 19-20, 2019 Vienna, Austria
&
7
th
World Heart Congress
24
th
World Congress on
Pharmacology
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conference
series
.com
Naranjan S Dhalla, Clin Pharmacol Biopharm, Volume 08
Antiplatelet agents as a novel therapy of heart failure due to myocardial infarction
Background
: Although different antiplatelet agents are used for the prevention of thrombosis and treatment of ischemic heart
disease, very little information regarding therapeutic potential of these agents in heart failure is available.
Objectives
:We have investigated the effects of some antiplatelet agents such as sarpogrelate (SAR) and cilostazol (CIL) treatments
on cardiac dysfunction, cardiac remodeling and subcellular defects in heart failure due to myocardial infection.
Methods
: Heart failure in rats was induced by including the coronary artery for 8 weeks and the drug treatment was started 4
weeks after inducing myocardial infarction.
Results
: Marked depression in cardiac output and ejection fraction as well as increases in heart rate, left ventricle (LV) thickness
and LV volume in the infarcted animals were attenuated by SAR and CIL. Alterations inmyofibril Ca
2+
-ATPase, as well as myosin
isozyme contents and gene expression in the failing heart were reduced by SAR and CIL. Likewise, changes in sarcoplasmic
reticular Ca
2+
-uptake and release activities, Ca
2+
-pump and Ca
2+
-release protein content as well as their mRNA levels were
attenuated by both drug treatments.
Conclusions
: These results provide evidence that both SAR and CIL delay the progression of heart failure and improve cardiac
function by attenuating cardiac remodeling, subcellular defects and abnormalities in cardiac gene expression. It is suggested that
antiplatelet agents may prove to be a viable therapy for the treatment of heart failure. (Infrastructure support for this study was
provided by the St. Boniface Hospital Foundation)
Recent Publications
1.
Dhalla N S, Takeda N, Rodriguez-Leyva D and Elimban V (2014) Mechanisms of subcellular remodelling in heart
failure due to diabetes. Heart Fail Rev 19(1):87-99.
2.
Dhalla N S, Rangi S, Babick A P, Zieroth S and Elimban V (2012) Cardiac remodeling and subcellular defects in heart
failure due to myocardial infarction and aging. Heart Fail Rev 17(4-5):671-681.
3.
Machackova J, Sanganalmath S K, Elimban V and Dhalla N S (2011) β-adrenergic blockade attenuates cardiac
dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med 15(3):545-554.
4.
Dhalla N S, Saini-ChohanHK, Rodriguez-Leyva D, ElimbanV, Dent MR and Tappia P S (2009) Subcellular remodeling
may induce cardiac dysfunction in congestive heart failuren. Cardiovasc Res 81(3):429-438.
Biography
Naranjan S Dhalla is a Distinguished Professor and Director of Cardiovascular Developments, St. Boniface Hospital Albrechtsen Research Centre, Max Rady
College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, and Winnipeg, Canada.
Naranjan S Dhalla
University of Manitoba, Canada